Secondhand smoke exposure and other signs of tobacco consumption at outdoor entrances of primary schools in 11 European countries.


Journal

The Science of the total environment
ISSN: 1879-1026
Titre abrégé: Sci Total Environ
Pays: Netherlands
ID NLM: 0330500

Informations de publication

Date de publication:
15 Nov 2020
Historique:
received: 23 04 2020
revised: 24 06 2020
accepted: 02 07 2020
pubmed: 8 8 2020
medline: 17 9 2020
entrez: 8 8 2020
Statut: ppublish

Résumé

Although smoking restrictions at child-related settings are progressively being adopted, school outdoor entrances are neglected in most smoke-free policies across Europe. To describe secondhand smoke (SHS) exposure and tobacco-related signs in outdoor entrances of primary schools in Europe according to area-level socioeconomic status (SES), smoke-free policy, national smoking prevalence, and geographical region. In this cross-sectional study we monitored vapor-phase nicotine concentrations at 220 school outdoor entrances in 11 European countries (March 2017-October 2018). To account for nicotine presence, we used the laboratory's limit of quantification of 0.06 μg/m There were detectable levels of nicotine in 45.9% of the outdoor entrances, in 29.1% smell of smoke, in 43.2% people smoking, in 75.0% discarded butts, and in 14.6% ashtrays. Median nicotine concentration was below the laboratory's limit of quantification <0.06 μg/m Smoking at school outdoor entrances is a source of SHS exposure in Europe. These findings support the extension of smoking bans with a clear perimeter to the outdoor entrances of schools.

Identifiants

pubmed: 32758838
pii: S0048-9697(20)34267-4
doi: 10.1016/j.scitotenv.2020.140743
pii:
doi:

Substances chimiques

Tobacco Smoke Pollution 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

140743

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Elisabet Henderson (E)

Agència de Salut Pública de Barcelona, Pl. Lesseps, 1, 08023 Barcelona, Spain; Universitat Pompeu Fabra, Departament de Ciències Experimentals i de la Salut (DCEXS), Doctor Aiguader, 88, 08003 Barcelona, Spain; Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Av. Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 282029 Madrid, Spain.

Xavier Continente (X)

Agència de Salut Pública de Barcelona, Pl. Lesseps, 1, 08023 Barcelona, Spain; Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Av. Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 282029 Madrid, Spain; Sant Pau Institute of Biomedical Research (IIB Sant Pau), Sant Antoni Maria Claret, 167, 08025 Barcelona, Spain.

Esteve Fernández (E)

Tobacco Control Unit, Institut Català d'Oncologia, Av. Granvia de l'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat, Spain; Tobacco Control Research Group, Institut d'Investigació Biomèdica de Bellvitge, Av. Granvia de l'Hospitalet 199, 08908 L'Hospitalet de Llobregat, Spain; School of Medicine and Health Sciences, Universitat de Barcelona, Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Spain; Consortium for Biomedical Research in Respiratory Diseases (CIBERES), Av. Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 282029 Madrid, Spain.

Olena Tigova (O)

Tobacco Control Unit, Institut Català d'Oncologia, Av. Granvia de l'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat, Spain; Tobacco Control Research Group, Institut d'Investigació Biomèdica de Bellvitge, Av. Granvia de l'Hospitalet 199, 08908 L'Hospitalet de Llobregat, Spain; School of Medicine and Health Sciences, Universitat de Barcelona, Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Spain; Consortium for Biomedical Research in Respiratory Diseases (CIBERES), Av. Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 282029 Madrid, Spain.

Nuria Cortés-Francisco (N)

Agència de Salut Pública de Barcelona, Pl. Lesseps, 1, 08023 Barcelona, Spain; Sant Pau Institute of Biomedical Research (IIB Sant Pau), Sant Antoni Maria Claret, 167, 08025 Barcelona, Spain.

Silvano Gallus (S)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Department of Environmental Health Sciences, Via Mario Negri 2, 20156 Milan, Italy.

Alessandra Lugo (A)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Department of Environmental Health Sciences, Via Mario Negri 2, 20156 Milan, Italy.

Sean Semple (S)

Institute for Social Marketing and Health, University of Stirling, Stirling FK9 4LA, Scotland, UK.

Rachel O'Donnell (R)

Institute for Social Marketing and Health, University of Stirling, Stirling FK9 4LA, Scotland, UK.

Luke Clancy (L)

TobaccoFree Research Institute Ireland, Dublin, Ireland.

Sheila Keogan (S)

TobaccoFree Research Institute Ireland, Dublin, Ireland.

Ario Ruprecht (A)

Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1, 20133 Milan, Italy.

Alessandro Borgini (A)

Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1, 20133 Milan, Italy.

Anna Tzortzi (A)

George D. Behrakis Research Lab-Hellenic Cancer Society, 17 B Ipitou Street, 10557 Athens, Greece.

Vergina K Vyzikidou (VK)

George D. Behrakis Research Lab-Hellenic Cancer Society, 17 B Ipitou Street, 10557 Athens, Greece.

Giuseppe Gorini (G)

Istituto per lo Studio, la Prevenzione e la Rete Oncologica (ISPRO), Via Cosimo il Vecchio, 2, 50139 Florence, Italy.

Angel López-Nicolás (A)

Universidad Politécnica de Cartagena (UPCT), Plaza Cronista Isidoro Valverde, s/n, 30202 Cartagena, Spain.

Joan B Soriano (JB)

Consortium for Biomedical Research in Respiratory Diseases (CIBERES), Av. Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 282029 Madrid, Spain; Hospital Universitario La Princesa (IISP), Diego de León, 62, Planta 1, 28006 Madrid, Spain.

Gergana Geshanova (G)

Smoke-free Life Coalition, Slivnitsa Blvd, 257, 1202 Sofia, Bulgaria.

Joseph Osman (J)

OFT Conseil, Office Français de santé et bien-être au Travail, Rue Gobert, 12, 75011 Paris, France.

Ute Mons (U)

Cancer Prevention Unit & WHO Collaborating Centre for Tobacco Control, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, 280, 69120 Heidelberg, Germany.

Krzysztof Przewozniak (K)

Maria Sklodowska-Curie National Research Institute of Oncology, 15B Wawelska Str., 02-034, Warsaw, Poland; The Foundation Smart Health - Health in 3D, 24 Makolagwy Str., 02-811 Warsaw, Poland; Collegium Civitas, 1 Defilad Square, 00-901 Warsaw, Poland.

José Precioso (J)

Instituto de Educação, Universidade do Minho, 4710-057 Braga, Portugal.

Ramona Brad (R)

Healthy Romania Generation 2035 Association, Bucharest, Romania.

Maria J López (MJ)

Agència de Salut Pública de Barcelona, Pl. Lesseps, 1, 08023 Barcelona, Spain; Universitat Pompeu Fabra, Departament de Ciències Experimentals i de la Salut (DCEXS), Doctor Aiguader, 88, 08003 Barcelona, Spain; Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Av. Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 282029 Madrid, Spain; Sant Pau Institute of Biomedical Research (IIB Sant Pau), Sant Antoni Maria Claret, 167, 08025 Barcelona, Spain. Electronic address: mjlopez@aspb.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH